Clinical trials: Liver Diseases, Alcoholic
Fatty Liver Disease
Prevalence of Advanced Fibrosis in Patients Living With HIV
Monocentric, cross-sectional study to define the prevalence of advanced fibrosis in an HIV infected outpatient population. Follow-up over 10 years to assess clinical relevance.
- Trial name
- FLASH (NCT04066608)
- Where
- 2 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Johannes Gutenberg University Mainz
NAFLD, NASH
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children
This study will validate recently developed Magnetic Resonance Imaging (MRI) and Ultrasound (US) based methods for liver fat quantification in children with obesity and healthy range of body mass index (BMI).
- Trial name
- NCT06354491
- Testing
- Magnetic Resonance Imaging (MRI), Ultrasound (US)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Fatty Liver
Treatment for Non-Alcoholic Fatty Liver With Different Doses of Vitamin E
Background: Non-alcoholic fatty liver disease (NAFLD) is an excess accumulation of fat in the liver cells. It is associated with obesity, high blood pressure, high cholesterol, and diabetes.
- Trial name
- NCT01792115
- Testing
- Vitamin E 200 IU/d, Vitamin E 400 IU/d, Vitamin E 800 IU/d
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
De Novo Lipogenesis in Severity of NAFLD
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
- Trial name
- NCT03683589
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Missouri-Columbia
Severe Alcoholic Hepatitis
Rifaximin Use in Severe Alcoholic Hepatitis
This study aimed to investigate the effect of decontamination by rifaximin in severe alcoholic hepatitis patients. Patients who take corticosteroid or pentoxifylline will be randomly allocated to rifaximin group or control group.
- Trial name
- NCT02485106
- Testing
- Rifaximin, Corticosteroid or pentoxifylline
- Volunteers
- 170 people
- Sponsor
- Saint Vincent's Hospital, Korea
Hepatitis
S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis
The purpose of this study is to examine the effect of S-adenosylmethionine therapy in those patients with non-alcoholic liver disease in the form of steatohepatitis (NASH).
- Trial name
- NCT00108589
- Testing
- S-adenosylmethionine
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Nonalcoholic Steatohepatitis (NASH), Overweight or Obesity
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
This Phase 1/2 study will evaluate safety, efficacy, PK, and PD of FT-4101 as a single agent in overweight/obese subjects with NASH. The study may be conducted in up to 2 dosing cohorts.
- Trial name
- NCT04004325
- Testing
- FT-4101, Deuterated Water
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- Forma Therapeutics, Inc.
NASH (Nonalcoholic Steatohepatitis), NAFLD (Nonalcoholic Fatty Liver Disease)
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
The purpose of this study is to assess the effects of an investigational drug, PF-05221304 (PF'1304) on the way the liver handles fat.
- Trial name
- NCT04395950
- Testing
- PF-05221304
- Sponsor
- Columbia University
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from simple fatty liver over steatohepatitis (NASH) to liver cirrhosis and cancer (HCC) and is a major and increasing health problem affecting nearly 40% of…
- Trial name
- NCT02075164
- Testing
- Fructose, Glucose
- Where
- Austria
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Prof. Michael Trauner, MD
NASH, NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled.
- Conditions
- NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2
- Trial name
- NCT04702490
- Testing
- MET409 Active, Empagliflozin
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Metacrine, Inc.
Metabolic Associated Fatty Liver Disease
A Prospective Cohort Study of Metabolic Associated Fatty Liver Disease in China
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new concept proposed in 2020. Unlike non-alcoholic fatter liver disease (NAFLD), the diagnosis of MAFLD requires the presence any of the following 3 metabolic…
- Trial name
- NCT04573283
- Where
- China
- Volunteers
- 3,000 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Nonalcoholic Fatty Liver Disease
Elucidating Growth Hormone Dynamics at Stages of Progressive Nonalcoholic Fatty Liver Disease
The purpose of this study is to investigate relationships between the body's growth hormone "axis" and nonalcoholic fatty liver disease.
- Trial name
- NCT06166797
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
NAFLD, Non-alcoholic Fatty Liver Disease
Comparing Effects of Beetroot Juice and Mediterranean Diet on Liver Enzymes and Sonography in Patients With NAFLD
The goal of this clinical trial study is to investigate comparing Effects of Beetroot juice and Mediterranean diet on Liver Enzymes and Sonographic appearance in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) The main…
- Trial name
- BJ (NCT05909631)
- Testing
- Beetroot juice, Mediterranean diet alone (MeD), Mediterranean diet with beet juice (BJ+MeD)
- Where
- Iraq
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Sulaimani Polytechnic University
Non-Alcoholic Fatty Liver Disease
Porphyromonas Gingivalis and Severity of Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
Many studies suggest that Porphyromonas gingivalis, a virulent periodontopathogenic bacterium, is associated with many systemic diseases such as cardiovascular diseases.
- Trial name
- BUCCONAFLD (NCT05654129)
- Testing
- saliva samples, medical questionnaire
- Where
- France
- Volunteers
- 182 people
- Sponsor
- University Hospital, Toulouse
Intrahepatic Cholestasis Associated With Alcoholic Liver Disease
Study With Heptral in Subjects With Liver Disease Due to Alcohol Consumption
A research study of an approved drug called Heptral®, ademetionine, to treat adults with intrahepatic cholestasis (a condition where bile cannot flow from the liver to the duodenum) in pre-cirrhotic and cirrhotic states.
- Trial name
- NCT02200029
- Testing
- Ademetionine IV+tablet, Ademetionine tablet
- Where
- 12 sites in Russia
- Volunteers
- 75 people
- Sponsor
- Abbott
Non-alcoholic Fatty Liver Disease
The Metabolic Effects of Ginseng Oligopeptide Preparation on Non- Alcoholic Fatty Liver Disease With Obesity: a Randomized Controlled Double-blind Trial
To investigate the effect of ginseng oligopeptide on nonalcoholic fatty liver disease with obesity and clarify its intervention mechanism in theory, which will contribute to the prevention and treatment of non-alcoholic fatty…
- Trial name
- NCT06167902
- Testing
- Ginseng oligopeptide (Ginseng extract）, Maltodextrin
- Volunteers
- 200 people
- Sponsor
- Peking Union Medical College Hospital
Chronic Hepatitis B, Hepatic Fibrosis
Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD
Hepatic steatosis and insulin resistance are associated with severity of fibrosis in non-alcoholic fatty liver disease (NAFLD) and chronic hepatitis C.
- Conditions
- Chronic Hepatitis B, Hepatic Fibrosis, Fatty Liver
- Trial name
- NCT02031913
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Seoul National University Boramae Hospital
Non-alcoholic Steatohepatitis (NASH)
A Study to Assess Safety, Tolerability, PK and PD of AZD2693 in Non-alcoholic Steatohepatitis Patients
This study is intended to investigate the safety and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD2693, following subcutaneous (SC) administration of multiple ascending doses in participants with…
- Trial name
- NCT04483947
- Testing
- AZD2693
- Where
- 16 sites in United States
- Volunteers
- 74 people
- Sponsor
- AstraZeneca
Nonalcoholic Steatohepatitis (NASH), Nonalcoholic Fatty Liver Disease (NAFLD)
Safety, Tolerability, and Efficacy of Selonsertib, Firsocostat, and Cilofexor in Adults With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of selonsertib, firsocostat, cilofexor, fenofibrate and/or Vascepa® in adults with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic…
- Trial name
- NCT02781584
- Testing
- SEL, FIR, CILO
- Where
- 13 sites in United States, New Zealand
- Volunteers
- 220 people
- Sponsor
- Gilead Sciences
Renal Impairment
Role Of Serum Adiponectin In The Ealy Detection Of Renal Impairment In Patients With Non Alcoholic Fatty Liver Disease
Early detection of renal impairment in patients with Non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.
- Trial name
- NCT05556135
- Testing
- level of serun adiponectin
- Volunteers
- 90 people
- Sponsor
- Assiut University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.